{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:35:50Z","timestamp":1771529750299,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01914-8","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:54:33Z","timestamp":1758876873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of PSMA PET\/CT radiomics analysis for risk stratification in newly diagnosed prostate cancer: a multicenter study"],"prefix":"10.1186","volume":"25","author":[{"given":"Esmail","family":"Jafari","sequence":"first","affiliation":[]},{"given":"Amin","family":"Zarei","sequence":"additional","affiliation":[]},{"given":"Habibollah","family":"Dadgar","sequence":"additional","affiliation":[]},{"given":"Ahmad","family":"Keshavarz","sequence":"additional","affiliation":[]},{"given":"Hamid","family":"Abdollahi","sequence":"additional","affiliation":[]},{"given":"Rezvan","family":"Samimi","sequence":"additional","affiliation":[]},{"given":"Reyhaneh","family":"Manafi-Farid","sequence":"additional","affiliation":[]},{"given":"GhasemAli","family":"Divband","sequence":"additional","affiliation":[]},{"given":"Babak","family":"Nikkholgh","sequence":"additional","affiliation":[]},{"given":"Babak","family":"Fallahi","sequence":"additional","affiliation":[]},{"given":"HamidReza","family":"Amini","sequence":"additional","affiliation":[]},{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"additional","affiliation":[]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[]},{"given":"Farshad","family":"Zohrabi","sequence":"additional","affiliation":[]},{"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"2","key":"1914_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"key":"1914_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68 Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1914_CR3","doi-asserted-by":"crossref","unstructured":"Egevad L, Delahunt B, Srigley JR, Samaratunga H. International society of urological pathology (ISUP) grading of prostate cancer\u2013An ISUP consensus on contemporary grading. Wiley Online Library; 2016. pp. 433\u20135.","DOI":"10.1111\/apm.12533"},{"key":"1914_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fsurg.2020.00007","volume":"7","author":"M Wenzel","year":"2020","unstructured":"Wenzel M, Theissen L, Preisser F, Lauer B, Wittler C, Humke C, et al. Complication rates after TRUS guided transrectal systematic and MRI-targeted prostate biopsies in a high-risk region for antibiotic resistances. Front Surg. 2020;7:7.","journal-title":"Front Surg"},{"key":"1914_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","volume":"44","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1914_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s11307-019-01445-z","volume":"22","author":"H Dadgar","year":"2020","unstructured":"Dadgar H, Emami F, Norouzbeigi N, Vafaee MS, Jafari E, Gholamrezanezhad A, et al. Application of [68Ga]PSMA PET\/CT in diagnosis and management of prostate cancer patients. Mol Imaging Biol. 2020;22:1062\u20139.","journal-title":"Mol Imaging Biol"},{"key":"1914_CR7","doi-asserted-by":"crossref","unstructured":"Dadgar H, Seyedi Vafaee M, Norouzbeigi N, Jafari E, Gholamrezanezhad A, Assadi M. Dual-phase 68Ga-PSMA-11 PET\/CT May increase the rate of detected lesions in prostate cancer patients. Urol J. 2021. 0391560321993544.","DOI":"10.1177\/0391560321993544"},{"issue":"1","key":"1914_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00259-023-06418-7","volume":"51","author":"I Shiri","year":"2023","unstructured":"Shiri I, Salimi Y, Maghsudi M, Jenabi E, Harsini S, Razeghi B, et al. Differential privacy preserved federated transfer learning for multi-institutional 68Ga-PET image artefact detection and disentanglement. Eur J Nucl Med Mol Imaging. 2023;51(1):40\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1914_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4103\/wjnm.WJNM_78_19","volume":"19","author":"E Jafari","year":"2020","unstructured":"Jafari E, Ahmadzadehfar H, Dadgar H, Assadi M. An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay. World J Nucl Med. 2020;19:260.","journal-title":"World J Nucl Med"},{"issue":"1","key":"1914_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40336-022-00525-5","volume":"11","author":"N Jokar","year":"2023","unstructured":"Jokar N, Moradhaseli F, Ahmadzadehfar H, Jafari E, Nikeghbalian S, Rasekhi AR, Assadi M. Theranostic approach in liver cancer: an emerging paradigm to optimize personalized medicine. Clin Translational Imaging. 2023;11(1):51\u201370.","journal-title":"Clin Translational Imaging"},{"issue":"8","key":"1914_CR11","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","volume":"46","author":"N Jokar","year":"2021","unstructured":"Jokar N, Velikyan I, Ahmadzadehfar H, Rekabpour SJ, Jafari E, Ting HH, et al. Theranostic approach in breast cancer: A treasured tailor for future oncology. Clin Nucl Med. 2021;46(8):e410\u201320.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1914_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cpet.2021.03.005","volume":"16","author":"H Shooli","year":"2021","unstructured":"Shooli H, Nemati R, Ahmadzadehfar H, Aboian M, Jafari E, Jokar N, et al. Theranostics in brain tumors. PET Clin. 2021;16(3):397\u2013418.","journal-title":"PET Clin"},{"issue":"4","key":"1914_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403\u201317.","journal-title":"Eur Urol"},{"key":"1914_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00259-018-4160-7","volume":"46","author":"P Donato","year":"2019","unstructured":"Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, et al. Improved specificity with 68 Ga PSMA PET\/CT to detect clinically significant lesions invisible on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging. 2019;46:20\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1914_CR15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436\u201343.","journal-title":"J Urol"},{"key":"1914_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/RLU.0000000000002824","volume":"44","author":"M Assadi","year":"2019","unstructured":"Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, et al. 177Lu-PSMA and 177Lu-DOTATATE therapy in a patient with metastatic Castration-Resistant prostate cancer and neuroendocrine differentiation. Clin Nucl Med. 2019;44:978\u201380.","journal-title":"Clin Nucl Med"},{"key":"1914_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/wjnm.WJNM_20_19","volume":"19","author":"M Assadi","year":"2020","unstructured":"Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, et al. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: initial clinical experience after 2 years. World J Nucl Med. 2020;19:15\u201320.","journal-title":"World J Nucl Med"},{"issue":"3","key":"1914_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MNM.0000000000001327","volume":"42","author":"E Jafari","year":"2021","unstructured":"Jafari E, Ahmadzadehfar H, Bagheri D, Amini A, Assadi M. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C. Nucl Med Commun. 2021;42(3):325\u201331.","journal-title":"Nucl Med Commun"},{"key":"1914_CR19","doi-asserted-by":"crossref","unstructured":"Jafari E, Amini AL, Ahmadzadehfar H, Bagheri D, Assadi M. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors. Nuklearmedizin. 2021.","DOI":"10.1055\/a-1332-8230"},{"issue":"1","key":"1914_CR20","first-page":"3","volume":"32","author":"E Jafari","year":"2024","unstructured":"Jafari E, Assadi M, Eftekhari M. Production of the state of the Art therapeutic radiopharmaceuticals in iran, from beta-to alpha-emitting targeted radionuclide therapy: clinical advances and perspectives. Iran J Nuclear Med. 2024;32(1):3\u20138.","journal-title":"Iran J Nuclear Med"},{"key":"1914_CR21","doi-asserted-by":"crossref","unstructured":"Jafari E, Manafi-Farid R, Ahmadzadehfar H, Salek F, Jokar N, Keshavarz A et al. Prognostic significance of baseline clinical and [68Ga]Ga-PSMA PET derived parameters on biochemical response, overall survival, and PSA Progression-Free survival in metastatic Castration-Resistant prostate cancer (mCRPC) patients undergoing [177Lu]Lu-PSMA therapy. Nuklearmedizin. 2024(EFirst).","DOI":"10.1055\/a-2365-8113"},{"key":"1914_CR22","doi-asserted-by":"publisher","first-page":"1066926","DOI":"10.3389\/fonc.2022.1066926","volume":"12","author":"M Assadi","year":"2022","unstructured":"Assadi M, Manafi-Farid R, Jafari E, Keshavarz A, Divband G, Moradi MM, et al. Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. Front Oncol. 2022;12:1066926.","journal-title":"Front Oncol"},{"key":"1914_CR23","doi-asserted-by":"publisher","first-page":"1018833","DOI":"10.3389\/fonc.2022.1018833","volume":"12","author":"Z Wang","year":"2022","unstructured":"Wang Z, Li Y, Zheng A, Gao J, Yuan W, Shen C, et al. Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET\/CT for risk stratification in newly diagnosed prostate cancer. Front Oncol. 2022;12:1018833.","journal-title":"Front Oncol"},{"issue":"10","key":"1914_CR24","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s11547-022-01541-1","volume":"127","author":"F Yao","year":"2022","unstructured":"Yao F, Bian S, Zhu D, Yuan Y, Pan K, Pan Z, et al. Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with 18F-PSMA-1007 PET: comparison among different volume segmentation thresholds. Radiol Med. 2022;127(10):1170\u20138.","journal-title":"Radiol Med"},{"issue":"2","key":"1914_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2967\/jnumed.121.262464","volume":"63","author":"F Orlhac","year":"2022","unstructured":"Orlhac F, Eertink JJ, Cottereau A-S, Zijlstra JM, Thieblemont C, Meignan M, et al. A guide to combat harmonization of imaging biomarkers in multicenter studies. J Nucl Med. 2022;63(2):172\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"1914_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40336-024-00666-9","volume":"12","author":"E Jafari","year":"2024","unstructured":"Jafari E, Dadgar H, Zarei A, Samimi R, Manafi-Farid R, Divband G, et al. The role of [68Ga]Ga-PSMA PET\/CT in primary staging of newly diagnosed prostate cancer: predictive value of PET-derived parameters for risk stratification through machine learning. Clin Translational Imaging. 2024;12(6):669\u201382.","journal-title":"Clin Translational Imaging"},{"issue":"4","key":"1914_CR27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/jmri.27132","volume":"52","author":"L Gong","year":"2020","unstructured":"Gong L, Xu M, Fang M, Zou J, Yang S, Yu X, et al. Noninvasive prediction of high-grade prostate cancer via biparametric MRI radiomics. J Magn Reson Imaging. 2020;52(4):1102\u20139.","journal-title":"J Magn Reson Imaging"},{"key":"1914_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00259-020-04971-z","volume":"48","author":"MCF Cysouw","year":"2021","unstructured":"Cysouw MCF, Jansen BHE, van de Brug T, Oprea-Lager DE, Pfaehler E, de Vries BM, et al. Machine learning-based analysis of [18 F] DCFPyL PET radiomics for risk stratification in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:340\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1914_CR29","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00259-023-06136-0","volume":"50","author":"A Basso Dias","year":"2023","unstructured":"Basso Dias A, Mirshahvalad SA, Ortega C, Perlis N, Berlin A, van der Kwast T, et al. The role of [18F]-DCFPyL PET\/MRI radiomics for pathological grade group prediction in prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(7):2167\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1914_CR30","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1007\/s00259-023-06187-3","volume":"50","author":"S Ghezzo","year":"2023","unstructured":"Ghezzo S, Mapelli P, Bezzi C, Samanes Gajate AM, Brembilla G, Gotuzzo I, et al. Role of [68Ga] Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(8):2548\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1914_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00259-021-05430-z","volume":"49","author":"EL Solari","year":"2022","unstructured":"Solari EL, Gafita A, Schachoff S, Bogdanovi\u0107 B, Villagr\u00e1n Asiares A, Amiel T, et al. The added value of PSMA PET\/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging. 2022;49(2):527\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1914_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s13139-023-00832-3","volume":"58","author":"R Kumar","year":"2024","unstructured":"Kumar R, Ramachandran A, Mittal BR, Singh H. Convoluted neural network for detection of clinically significant prostate cancer on 68 Ga PSMA PET\/CT delayed imaging by analyzing radiomic features. Nuclear Med Mol Imaging. 2024;58(2):62\u20138.","journal-title":"Nuclear Med Mol Imaging"},{"key":"1914_CR33","doi-asserted-by":"crossref","unstructured":"Wang Z, Li Y, Zheng A, Gao J, Yuan W, Shen C et al. Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET\/CT for risk stratification in newly diagnosed prostate cancer. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.1018833"},{"key":"1914_CR34","doi-asserted-by":"crossref","unstructured":"Dadgar H, Hong X, Karimzadeh R, Ibragimov B, Majidpour J, Arabi H, et al. The value of artificial intelligence in PSMA PET: a pathway to improved efficiency and results. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian association of nuclear medicine (. AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of; 2025.","DOI":"10.23736\/S1824-4785.25.03640-4"},{"issue":"3","key":"1914_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14737159.2023.2192351","volume":"23","author":"L Filippi","year":"2023","unstructured":"Filippi L, Urso L, Bianconi F, Palumbo B, Marzola MC, Evangelista L, Schillaci O. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. Expert Rev Mol Diagn. 2023;23(3):243\u201355.","journal-title":"Expert Rev Mol Diagn"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01914-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:54:38Z","timestamp":1758876878000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01914-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01914-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Informed consent to participate was obtained from all of the participants in the study. This study was approved by the ethical committee of Bushehr University of Medical Sciences (Registration code: IR.BPUMS.REC.1403.015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}